|
|
Volumn 9, Issue 2, 2008, Pages 86-87
|
|
Quantifying hypertension in patients with cancer treated with sorafenib
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIHYPERTENSIVE AGENT;
NITRIC OXIDE;
SORAFENIB;
VASCULOTROPIN;
VASCULOTROPIN RECEPTOR;
BLOOD PRESSURE MEASUREMENT;
CLINICAL TRIAL;
DATA ANALYSIS;
DISEASE SEVERITY;
DRUG RESEARCH;
DRUG TARGETING;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
HYPERTENSION;
INCIDENCE;
INFORMATION PROCESSING;
KIDNEY CARCINOMA;
LETTER;
METHODOLOGY;
PATHOPHYSIOLOGY;
PATIENT CARE;
PATIENT MONITORING;
PRIORITY JOURNAL;
QUALITY CONTROL;
RISK ASSESSMENT;
TREATMENT OUTCOME;
UNITED STATES;
ANTINEOPLASTIC AGENTS;
BENZENESULFONATES;
HUMANS;
HYPERTENSION;
NEOPLASMS;
PYRIDINES;
VASCULAR ENDOTHELIAL GROWTH FACTOR A;
|
|
EID: 38549140603
PISSN: 14702045
EISSN: None
Source Type: Journal
DOI: 10.1016/S1470-2045(08)70009-3 Document Type: Letter |
|
Times cited : (11)
|
|
References (5)
|
